Coffee is widely consumed for its stimulating effects, but growing scientific evidence suggests that its health implications extend beyond alertness and energy. A large UK Biobank study published in Clinical Gastroenterology and Hepatology investigated the relationship between coffee consumption and liver health, finding that higher coffee intake was associated with lower risks of cirrhosis, liver cancer, and liver disease-related mortality. Imaging and plasma proteomic analyses further provided insights into potential mechanisms involving liver function, inflammation, and fibrosis. In addition, a study published in Beverage Plant Research identified three previously unreported diterpene esters in roasted Coffea arabica beans, named Caffaldehydes A, B, and C. All three demonstrated α-glucosidase inhibitory activity in vitro, with IC₅₀ values lower than that of acarbose under the study conditions. Together, these findings expand our understanding of coffee's potential health benefits, highlighting both population-level associations with liver health and the discovery of bioactive compounds that may contribute to glucose metabolism regulation. However, the clinical implications of these findings, particularly the effects of the newly identified compounds in humans, require further investigation.
From its familiar aroma to its stimulating effects, coffee has long been part of everyday life. Yet beyond its role as a popular beverage, coffee contains a complex mixture of bioactive compounds that have attracted growing scientific interest. In recent years, researchers have increasingly explored its potential relationship with liver health, metabolic regulation, inflammation, and other physiological processes.
Two recent studies offer complementary perspectives on these questions. One examines the association between coffee consumption and liver disease outcomes in a large population, supported by imaging and proteomic evidence. The other investigates the bioactive constituents of roasted coffee beans, identifying previously unreported diterpenes with promising glucose-regulating activity in laboratory experiments. Together, these studies provide new insights into the potential health value of coffee while highlighting the importance of distinguishing population-level associations from experimental findings.
1. Large-Scale Study Links Coffee Consumption to Better Liver Outcomes
A large study recently published in Clinical Gastroenterology and Hepatology addressed an important question concerning coffee and liver health. Researchers followed hundreds of thousands of participants for more than a decade and found that coffee consumption was significantly associated with a dose-dependent reduction in liver disease risk. The observed association remained regardless of genetic susceptibility to fatty liver disease or alcohol consumption habits.
The study drew on data from the UK Biobank and included 354,957 participants who had neither cirrhosis nor liver cancer at baseline. Two additional subcohorts were analyzed: 28,961 participants underwent liver MRI examinations, enabling detailed assessment of liver fat content, fibroinflammation, and iron burden; another 44,633 participants underwent plasma proteomic analysis covering 2,941 proteins to investigate potential underlying mechanisms.
To minimize the influence of confounding factors, the researchers adjusted for age, sex, smoking, alcohol consumption, body mass index, diabetes, the fatty liver disease susceptibility gene PNPLA3, and other variables that could affect liver disease risk. These adjustments were intended to reduce potential bias, including the possibility that coffee drinkers might differ from non-drinkers in other health-related behaviors.
Figure 1. Associations between coffee consumption and quantitative MRI-derived liver biomarkers.
After accounting for potential confounders, the study found a clear dose-response pattern: greater coffee consumption was associated with progressively lower risks of adverse liver outcomes.
Specifically, compared with participants who did not drink coffee, those who consumed 1–2 cups per day had a 20% lower risk of cirrhosis, a 24% lower risk of liver cancer, and a 31% lower risk of liver disease-related mortality. Among participants consuming five or more cups daily, the observed reductions were greater: 32% for cirrhosis, 47% for liver cancer, and 42% for liver disease-related mortality. All these trends were statistically significant.
These findings suggest that higher coffee consumption was associated with more favorable liver outcomes in this population. However, as an observational study, the findings do not establish that coffee consumption directly caused the reductions in risk.
The researchers also examined whether adding sugar or artificial sweeteners affected the observed associations. The overall association between coffee consumption and liver protection remained evident even among people who added these sweeteners. Nevertheless, MRI findings showed a slight increase in the cT1 measure, which reflects liver fibroinflammation, among participants who habitually used sweeteners.
In other words, although sugar and artificial sweeteners did not eliminate the overall association between coffee consumption and liver health, sweetener use was associated with a less favorable fibroinflammation-related imaging marker. Unsweetened coffee may therefore be a preferable option for those seeking to maximize potential health benefits, although the findings do not establish that sweeteners directly weaken coffee's anti-inflammatory effects.
Figure 2. Top coffee-associated proteins identified using the Olink panel for predicting cirrhosis events.
2. Potential Mechanisms: Insights From Plasma Proteomics
Why might coffee consumption be associated with better liver outcomes?
The plasma proteomic data from more than 44,000 participants offered clues at the molecular level. The researchers identified 74 proteins that were associated with both coffee consumption and cirrhosis risk.
On one hand, higher coffee consumption was associated with higher levels of proteins linked to normal liver function. These included transthyretin, which is associated with hepatic synthetic function, selenoprotein P, which is involved in antioxidant defense, and proteins related to complement regulation and inflammation. Their presence may reflect more favorable physiological conditions involving protein synthesis, antioxidant defenses, and inflammatory regulation.
On the other hand, several proteins associated with liver fibrosis and inflammatory activation were found at lower levels with increasing coffee consumption. Examples included MFAP4, a marker associated with fibrosis; CSF1R, which reflects macrophage-related inflammatory activity; and ENPP2, also known as autotaxin, which is closely associated with fibrotic progression.
Taken together, these findings suggest that coffee consumption may be associated with a molecular profile characterized by better-preserved liver-related functions and lower levels of proteins linked to inflammation and fibrosis. These associations provide possible mechanistic clues, but further research is needed to determine whether these proteins directly mediate the relationship between coffee and liver health.
The researchers also investigated differences between population subgroups. The association between coffee consumption and favorable liver outcomes remained evident regardless of alcohol consumption habits or the presence of the PNPLA3 susceptibility gene associated with fatty liver disease.
The association appeared weaker among participants with diabetes. The researchers proposed that the long-term metabolic disturbances associated with diabetes might partly counteract the potential anti-inflammatory and antifibrotic effects associated with coffee consumption. However, this interpretation requires further investigation.
3. Three Newly Identified Coffee Diterpenes Show Glucose-Regulating Potential
What compounds in coffee might contribute to its broader health effects?
A study published last year by a research team from the Chinese Academy of Sciences in Beverage Plant Research offers another perspective. The team developed an efficient, bioactivity-guided screening method and identified previously unreported bioactive diterpenes in roasted Arabica coffee beans. The researchers also demonstrated that these compounds exhibited promising glucose-regulating activity in vitro.
Diterpenes are characteristic bioactive constituents of coffee. Previous research has linked them to potential anti-inflammatory, anticancer, and glucose- and lipid-regulating activities. However, roasted coffee beans contain an extremely complex mixture of compounds, making it difficult for conventional isolation and purification techniques to identify trace constituents with biological activity.
To identify compounds with glucose-regulating potential, the researchers adopted a bioactivity-guided screening strategy. They first extracted a crude diterpene ester fraction from medium-roasted Coffea arabica beans and separated it into 19 fractions, designated Fr.1 through Fr.19, using silica gel column chromatography.
Each fraction was then subjected to two parallel analyses. Proton nuclear magnetic resonance spectroscopy (^1H NMR) was used to characterize its chemical composition, while α-glucosidase inhibitory activity was measured to assess its ability to inhibit an enzyme involved in carbohydrate digestion and glucose absorption.
Cluster heatmap analysis revealed that the fractions with the strongest inhibitory activity were concentrated in the Fr.9–Fr.13 range. These active fractions also shared characteristic aldehydic proton signals, suggesting that aldehyde-containing diterpenes might be key contributors to the observed glucose-regulating activity.
Figure 3. Cluster heatmap of coffee diterpene fractions based on ^1H NMR data.
4. Isolation and Identification of Caffaldehydes A, B, and C
After identifying the fractions of interest, the researchers selected Fr.9 for further purification using semipreparative high-performance liquid chromatography.
Three major peaks eluted at approximately 16, 24, and 31 minutes, respectively. Following purification, the researchers obtained three compounds in quantities of 8.6 mg, 3.4 mg, and 3.1 mg.
Structural characterization using nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry revealed that all three compounds had not previously been reported. They were named Caffaldehyde A, Caffaldehyde B, and Caffaldehyde C.
The three compounds shared a core coffee diterpene structure containing an aldehyde group, an enone moiety, and a lactone ring. They differed in the fatty acid components esterified to their structures:
-
Caffaldehyde A (1): Contains palmitic acid, a 16-carbon saturated fatty acid.
-
Caffaldehyde B (2): Contains stearic acid, an 18-carbon saturated fatty acid.
-
Caffaldehyde C (3): Contains arachidic acid, a 20-carbon saturated fatty acid.
Figure 4. Structures of compounds 1–3 and their IC₅₀ values for α-glucosidase inhibition.
5. α-Glucosidase Inhibitory Activity of the Three Compounds
Activity testing showed that all three newly identified compounds exhibited α-glucosidase inhibitory activity. Their IC₅₀ values were 45.07 ± 3.16 μM, 24.40 ± 0.33 μM, and 17.50 ± 2.86 μM, respectively.
Under the experimental conditions, all three compounds had lower IC₅₀ values than acarbose, a clinically used glucose-lowering medication, which had an IC₅₀ value of 60.71 ± 16.45 μM in the same comparison.
The results also revealed a relationship between fatty acid chain length and inhibitory activity: compounds containing longer fatty acid chains showed stronger α-glucosidase inhibition. Among the three compounds, Caffaldehyde C, which contains a 20-carbon fatty acid, exhibited the strongest activity.
These findings identify Caffaldehydes A, B, and C as promising candidates for further investigation into the glucose-regulating potential of coffee-derived compounds. Nevertheless, the results were obtained from an in vitro enzyme inhibition assay. They do not establish that these compounds lower blood glucose in humans or that they are more effective than acarbose in clinical use. Further studies are needed to investigate their bioavailability, safety, mechanisms of action, and effects in living organisms.
Figure 5. (a) Diterpene-containing MN1; (b) proposed formation pathways of characteristic fragments of compounds 1–6.
Conclusion
Taken together, these two studies extend our understanding of coffee beyond its familiar role as a stimulating beverage.
At the basic research level, scientists have identified previously unreported diterpene esters in roasted coffee beans. Three of these compounds demonstrated α-glucosidase inhibitory activity in vitro, with IC₅₀ values lower than that of acarbose under the experimental conditions. These findings provide new chemical evidence that may help explain some of coffee's potential relevance to glucose metabolism.
At the population research level, a study involving approximately 355,000 participants, with follow-up extending over more than a decade, combined clinical outcomes with objective liver imaging and plasma proteomic evidence. The findings showed that coffee consumption was associated with lower risks of cirrhosis, liver cancer, and liver disease-related mortality, with stronger associations observed at higher intake levels.
Together, these studies highlight two complementary areas of scientific interest: the relationship between coffee consumption and liver health, and the identification of specific compounds that may contribute to its biological activities.
However, the evidence should be interpreted cautiously. Observational associations do not establish causation, and promising results from laboratory experiments do not necessarily translate into clinical benefits. Further research will be needed to clarify the mechanisms involved, establish appropriate consumption levels, and determine whether newly identified coffee diterpenes have meaningful effects on human health.
References
-
Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.035
-
Bioactive oriented discovery of diterpenoids in Coffea arabica basing on 1D NMR and LC-MS/MS molecular network. Beverage Plant Research. DOI: 10.48130/bpr-0024-0035